TGFB1 and neoplasm: Sanjeev et al. found that TGF-β1 can reshape the tumor microenvironment and limit the movement of T cells; the combination of TGF-β1 blockers and PDL1 blockers could inhibit the TGF-β1 pathway in stromal cells, therefore facilitating T cell entry in the tumor, stimulating antitumor immunity and causing cancer cell death [17,18].